Supplementary Figure S6 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> Fusions

Abstract

&lt;p&gt;Supplementary Figure S6 shows additional analysis of seribantumab efficacy in the ovarian cancer PDX OV-10-0050&lt;/p&gt;